Dianthus Therapeutics Stock Performance
| DNTH Stock | 19.49 0.95 4.65% |
The firm shows a Beta (market volatility) of 1.5, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Dianthus Therapeutics will likely underperform. At this point, Dianthus Therapeutics has a negative expected return of -0.15%. Please make sure to confirm Dianthus Therapeutics' potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Dianthus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Dianthus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (4.65) | Five Day Return (5.85) | Year To Date Return (15.99) | Ten Year Return (91.61) | All Time Return (91.61) |
Last Split Factor 1:16 | Last Split Date 2023-09-12 |
1 | Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology Annual Meeting | 12/31/2024 |
2 | Acquisition by Garcia Marino of 275000 shares of Dianthus Therapeutics at 17.88 subject to Rule 16b-3 | 01/14/2025 |
3 | Acquisition by Garcia Marino of 340000 shares of Dianthus Therapeutics at 22.07 subject to Rule 16b-3 | 02/03/2025 |
4 | Acquisition by Ryan Savitz of 150000 shares of Dianthus Therapeutics at 22.07 subject to Rule 16b-3 | 02/04/2025 |
5 | Octagon Capital Advisors LP Increases Stake in Dianthus Therapeu - GuruFocus.com | 02/05/2025 |
6 | Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences | 02/26/2025 |
7 | Insider Trading | 03/04/2025 |
8 | Dianthus Therapeutics Stock Price Up 8.2 percent - Heres What Happened - MarketBeat | 03/06/2025 |
9 | Acquisition by Veness Adam M of 110000 shares of Dianthus Therapeutics at 17.88 subject to Rule 16b-3 | 03/07/2025 |
10 | Dianthus Therapeutics GAAP EPS of -0.81 beats by 0.04, revenue of 1.33M beats by 0.47M | 03/11/2025 |
11 | Stifel maintains Buy rating on Dianthus Therapeutics stock - Investing.com India | 03/12/2025 |
12 | Dianthus Therapeutics Full Year 2024 Earnings Beats Expectations | 03/13/2025 |
13 | Dianthus Therapeutics Stock Price Down 3.8 percent - Heres What Happened - MarketBeat | 03/20/2025 |
| Begin Period Cash Flow | 132.4 M | |
| Free Cash Flow | -78.3 M |
Dianthus |
Dianthus Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,290 in Dianthus Therapeutics on December 24, 2024 and sell it today you would lose (341.00) from holding Dianthus Therapeutics or give up 14.89% of portfolio value over 90 days. Dianthus Therapeutics is currently does not generate positive expected returns and assumes 4.9012% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Dianthus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dianthus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dianthus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dianthus Therapeutics, and traders can use it to determine the average amount a Dianthus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0298
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DNTH |
Estimated Market Risk
| 4.9 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Dianthus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dianthus Therapeutics by adding Dianthus Therapeutics to a well-diversified portfolio.
Dianthus Therapeutics Fundamentals Growth
Dianthus Stock prices reflect investors' perceptions of the future prospects and financial health of Dianthus Therapeutics, and Dianthus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dianthus Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (24.07) % | ||||
| Current Valuation | 352.37 M | ||||
| Shares Outstanding | 32.13 M | ||||
| Price To Book | 1.78 X | ||||
| Price To Sales | 100.42 X | ||||
| Revenue | 6.24 M | ||||
| Gross Profit | 6.24 M | ||||
| EBITDA | (101.86 M) | ||||
| Net Income | (84.97 M) | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 11.33 X | ||||
| Cash Flow From Operations | (78.18 M) | ||||
| Earnings Per Share | (2.55) X | ||||
| Market Capitalization | 626.12 M | ||||
| Total Asset | 374.01 M | ||||
| Retained Earnings | (174.39 M) | ||||
| Working Capital | 262.45 M | ||||
About Dianthus Therapeutics Performance
By evaluating Dianthus Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Dianthus Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dianthus Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dianthus Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.9 K | 2 K | |
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.24) | (0.25) |
Things to note about Dianthus Therapeutics performance evaluation
Checking the ongoing alerts about Dianthus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dianthus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dianthus Therapeutics generated a negative expected return over the last 90 days | |
| Dianthus Therapeutics has high historical volatility and very poor performance | |
| Dianthus Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.24 M. Net Loss for the year was (84.97 M) with profit before overhead, payroll, taxes, and interest of 6.24 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Dianthus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Dianthus Therapeutics Stock Price Down 3.8 percent - Heres What Happened - MarketBeat |
- Analyzing Dianthus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dianthus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dianthus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dianthus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dianthus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dianthus Therapeutics' stock. These opinions can provide insight into Dianthus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |